Methods for treating myocardial infarction comprising administering an IL-6 inhibitor

Patent metadata

Field	Value
Publication number	US-8945558-B2
Application number	US-9067606-A
Country	US
Kind code	B2
Filing date	Oct 20, 2006
Priority date	Oct 21, 2005
Publication date	Feb 3, 2015
Grant date	Feb 3, 2015

Abstract

The present inventors investigated the effects of anti-IL-6 receptor antibodies on improving the condition of infarcted areas in myocardial infarction, and on suppressing left ventricular remodeling after myocardial infarction. As a result, the administration of anti-IL-6 receptor antibodies significantly suppressed the increase of MPO activity in the infarcted area and suppressed myocardial MCP-1 expression in both the infarcted area and the non-infarcted area. Furthermore, echocardiography and histological examinations revealed that cardiac hypertrophy is also suppressed.

First claim

The invention claimed is:

1. A method for treating a myocardial infarction in a subject, the method comprising:
providing an interleukin-6 (IL-6) inhibitor, wherein the IL-6 inhibitor is an antibody that recognizes an IL-6 receptor; and
administering the antibody parenterally to a subject who has developed a myocardial infarction, thereby treating the myocardial infarction.

2. The method of claim 1 , wherein the antibody is a monoclonal antibody.

3. The method of claim 1 , wherein the antibody is an antibody against a human IL-6 receptor.

4. The method of claim 1 , wherein the antibody is a recombinant antibody.

5. The method of claim 1 , wherein the antibody is a chimeric antibody, humanized antibody, or human antibody.

6. The method of claim 1 , wherein the method further comprises monitoring the subject by echocardiography.

7. The method of claim 1 , wherein the antibody is administered by injection.

8. The method of claim 1 , wherein the antibody is administered by use of a catheter.

9. A method for suppressing left ventricular remodeling after a myocardial infarction in a subject, the method comprising:
providing an interleukin-6 (IL-6) inhibitor, wherein the IL-6 inhibitor is an antibody that recognizes an IL-6 receptor; and
administering the antibody parenterally to a subject who has developed a myocardial infarction and is suffering from or at risk of developing left ventricular remodeling, thereby suppressing left ventricular remodeling.

10. The method of claim 9 , wherein the antibody is a monoclonal antibody.

11. The method of claim 9 , wherein the antibody is an antibody against a human IL-6 receptor.

12. The method of claim 9 , wherein the antibody is a recombinant antibody.

13. The method of claim 9 , wherein the antibody is a chimeric antibody, humanized antibody, or human antibody.

14. The method of claim 9 , wherein the method further comprises monitoring the subject by echocardiography.

15. The method of claim 9 , wherein the antibody is administered by injection.

16. The method of claim 9 , wherein the antibody is administered by use of a catheter.

Assignees

• Kobara Miyuki
• Chugai Pharmaceutical Co Ltd

Inventors

• Kobara Miyuki

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• Y10S930/141

  Interleukin · CPC title

• A61K39/3955 Primary

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title